alexa Fusion of MRI and TRUS Images
ISSN: 2168-9857
Medical & Surgical Urology
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Fusion of MRI and TRUS Images for Targeted Biopsy of Prostate

Sarfraz Ahmad*

Aberdeen Royal Infirmary Hospital, NHS Grampian, Aberdee, UK

*Corresponding Author:
MR. Sarfraz Ahmad
SpR Urology, Aberdeen Royal Infirmary Hospital
NHS Grampian, Aberdeen, UK
Tel: 44 7546712151
E-mail: [email protected]

Received date: February 28, 2014; Accepted date: March 04, 2014; Published date: March 08, 2014

Citation: Ahmad S (2014) Fusion of MRI and TRUS Images for Targeted Biopsy of Prostate. Med Surg Urol 3:e108. doi: 10.4172/2168-9857.1000e108

Copyright: © 2014 Ahmad S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Medical & Surgical Urology

Transrectal Ultrasound (TRUS) guided biopsy relies on systematic sampling of the prostate and it is one of the main interventional methods for the diagnosis of Prostate Cancer (PCa) [1]. On TRUS, PCa foci usually appear as hypoechoic lesions in the peripheral zone (PZ) of prostate. However, the hypoechoic areas are not pathognomonic for PCa, as 39% of all the cancers are isoechoic and some may be hyperechoic [2]. This limitation of the grey scale ultrasound is the logic of not replacing current practice of systematic biopsies with TRUS guided targeted biopsies (of hypoechoic areas). Urologist are frequently presented with the dilemma of a patient who has had one or more negative prostate biopsies yet continues to have an elevated PSA or abnormal digital rectal examination. Often these patients have undergone multiple TRUS guided biopsies despite the welldocumented decline in cancer detection with each successive biopsy [3].

In recent years, Magnetic Resonance Imaging (MRI) has emerged as powerful tool for diagnosis and staging of PCa. MRI allows an exact delineation of the zonal anatomy of the prostate, it’s surrounding structures and thus improves the detection of cancerous lesions. Enhanced MRI techniques [dynamic contrast-enhanced MRI (DCEMRI), diffusion-weighted MRI (DW-MRI) and magnetic resonance spectroscopy (MRS)] have further improved the diagnostic role of MRI. Pre biopsy MRI and real time TRUS images fusion (MRI/US fusion) targeted biopsies is an exciting technique to improve PCa detection especially in patients with prior negative biopsy. The cancer detection rates with MRI guidance are noticeably higher than TRUS, ranging from 38 % to 59 % [4]. Specific regions, such as the anterior part of the prostate, where more than 25 % of carcinomas occur, are insufficiently sampled by TRUS due to limitations in range with this method [5]. MRI/US fusion allows the sensitivity and specificity of MRI to be combined with real time capabilities of TRUS. Multiple techniques exist for MRI/US fusion and include (1) direct “in bore” MR biopsies, (2) cognitive fusion, and (3) MRI/US fusion via softwarebased image co-registration platforms [6,7]. Pinto et al. developed a novel platform that fuses pre-biopsy MRI with real time TRUS imaging to identify and biopsy lesions suspicious for PCa [8]. They reported that the PCa foci localised on MRI were successfully targeted using this platform. Furthermore, MRI/US fusion targeted biopsy detected more cancer per core than standard 12-core TRUS prostate biopsies [8]. Similarly, Marks et al. observed that MRI/US fusion targeted biopsies are 2-3 times more sensitive for detection of PCa than non-targeted systematic biopsies [7]. Additionally about 40% of men with Gleason score of 7 were diagnosed only by targeted biopsy and nearly 100% of men with highly suspicious MRI lesions were diagnosed with PCa [7].

MRI/US fusion allows urologists to progress from blind, systematic biopsies to biopsies, which are mapped, targeted and tracked. In future, MRI/US fusion targeted biopsy is likely to result in fewer and more accurate prostate biopsies than the present use of systematic biopsies with TRUS alone. However this is an evolving technique and limited data is available for MR targeted biopsies and no trial has compared MRI- targeted prostate biopsies with TRUS guided biopsies [4]. Robust scientific evidence from multi-centre randomised trials is required before the introduction of MRI/US fusion technique in routine urology practice. It will particularly be a useful option for men with suspected PCa and elevated PSA levels but previous negative biopsy.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11744
  • [From(publication date):
    June-2014 - Sep 22, 2017]
  • Breakdown by view type
  • HTML page views : 7952
  • PDF downloads :3792
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords